Dynavax Technologies’ (DVAX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $31.00 price target on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on DVAX. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $13.33 on Friday. The stock has a market cap of $1.75 billion, a PE ratio of 102.55 and a beta of 1.32. The business has a fifty day moving average of $12.81 and a two-hundred day moving average of $11.99. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $14.05. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.05. The company had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%. As a group, equities research analysts expect that Dynavax Technologies will post 0.2 earnings per share for the current fiscal year.

Institutional Trading of Dynavax Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Deep Track Capital LP increased its position in Dynavax Technologies by 42.0% in the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock worth $227,197,000 after purchasing an additional 5,265,000 shares during the period. Deerfield Management Company L.P. Series C increased its position in Dynavax Technologies by 23,990.1% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock worth $66,325,000 after purchasing an additional 5,172,263 shares during the period. Dimensional Fund Advisors LP increased its position in Dynavax Technologies by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company’s stock worth $51,948,000 after purchasing an additional 171,933 shares during the period. Renaissance Technologies LLC increased its position in Dynavax Technologies by 1.8% in the fourth quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company’s stock worth $30,077,000 after purchasing an additional 41,000 shares during the period. Finally, D. E. Shaw & Co. Inc. increased its position in Dynavax Technologies by 34.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock worth $24,497,000 after purchasing an additional 486,981 shares during the period. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.